35 completed, 7 recruiting, 5 terminated, 4 unknown. 28 Phase 2, 15 Phase 4, 9 Phase 1, 3 Phase 3, 2 Not applicable.
Follow Belatacept: new trials by email Literature Review of Belatacept trials Research Report on Belatacept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Antibody-Mediated Rejection (ABMR) With CarBel Carfilzomib, Belatacept - Kidney Transplant Rejection | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2026-05-27 | 2026-10-23 |
| Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO> Belatacept, anticalcineurins - Kidney Diseases | Phase 4 | Recruiting | University Hospital, Rouen | 44 | 2026-04-30 | 2026-06-09 |
| Belatacept in Heart Transplantation Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium - Heart Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 66 | 2025-01-29 | 2026-10-09 |
| Advancing Transplantation Outcomes in Children Sirolimus, Belatacept, Mycophenolate Mofetil - Kidney Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2024-05-22 | 2026-10-23 |
| Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination Tacrolimus, Belatacept - HBV, Kidney Transplantation | Unknown | University Hospital, Grenoble | 66 | 2024-03-15 | 2024-03-13 | |
| A Study of TCD601 in de Novo Renal Transplant Recipients TCD601, belatacept, ATG - Renal Transplantation | Phase 2 | Completed | ITB-Med LLC | 76 | 2023-12-28 | 2026-05-05 |
| Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept. Belatacept - Kidney Transplant Infection | Active not recruiting | University Hospital, Rouen | 28 | 2023-11-14 | 2026-05-22 | |
| Carfilzomib and Belatacept for Desensitization carfilzomib, belatacept, Bone marrow aspiration - Highly Sensitized Prospective Kidney Transplant Recipients | Phase 1 / Phase 2 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2021-12-28 | 2026-04-08 |
| Daratumumab and Belatacept for Desensitization daratumumab, belatacept, Bone marrow aspiration - Highly Sensitized Prospective Kidney Transplant Recipients | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 19 | 2021-11-01 | 2026-10-23 |
| Abatacept Conversion in Kidney Transplantation Belatacept, Abatacept - Renal Transplant Recipient | Phase 2 | Completed | Emory University | 87 | 2021-09-22 | 2026-09-16 |
| Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression Belatacept - Kidney Transplant Immunosuppression | Phase 4 | Completed | University of Texas Southwestern Medical Center | 25 | 2021-07-28 | 2026-08-14 |
| A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications Belatacept, Tacrolimus, Cyclosporine A - Renal Allograft Recipients | Phase 3 | Recruiting | Bristol-Myers Squibb | 102 | 2021-07-21 | 2026-08-31 |
| Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial) Belatacept, Everolimus, mycophenolate mofetil - Kidney Transplant Rejection | Phase 4 | Unknown | University of Cincinnati | 120 | 2021-04-09 | 2021-04-19 |
| Belatacept in De Novo Heart Transplantation Belatacept, Tacrolimus, Mycophenolate Mofetil - Heart Transplantation | Phase 2 | Recruiting | NYU Langone Health | 12 | 2020-08-06 | 2025-12-04 |
| Immune Monitoring to Facilitate Belatacept Monotherapy Allosure, Immunosuppression reduction, Trugraf - Kidney Transplant Rejection, Immunosuppression | Phase 4 | Completed | Massachusetts General Hospital | 17 | 2020-02-11 | 2023-12-04 |
| Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation Belatacept, Tacrolimus, ATG - Lung Transplant Rejection, Antibody-mediated Rejection | Phase 2 | Completed | Washington University School of Medicine | 27 | 2019-12-17 | 2022-11-25 |
| Treg Modulation With CD28 and IL-6 Receptor Antagonists lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone - Living-Donor Kidney Transplant, Kidney Transplant Recipients | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2019-12-11 | 2026-09-24 |
| A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant Belatacept, VIB4920, Thymoglobulin - Allografts, Rejection; Transplant, Kidney | Phase 2 | Completed | Amgen | 25 | 2019-10-30 | 2024-12-27 |
| Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Belatacept, Carfilzomib - Lung Transplant Rejection, Antibody-mediated Rejection | Phase 2 | Withdrawn | Duke University | 2019-05-01 | 2019-05-02 | |
| Precision Medicine Offers Belatacept Monotherapy Belatacept - Transplantation | Phase 4 | Withdrawn | University of California, San Francisco | 2019-02-01 | 2022-12-06 |
Showing 20 of 58. Sign in to see all of them.
Delayed Graft Function (4) · Diabetes Mellitus, Type 1 (3) · Kidney Failure, Chronic (3) · Rejection, Psychology (3) · Arthritis, Rheumatoid (1) · Hepatitis B (1) · Hypoglycemia (1) · Kidney Diseases (1) · Proteinuria (1) · Renal Insufficiency (1)
Bristol-Myers Squibb (14) · National Institute of Allergy and Infectious Diseases (NIAID) (12) · Emory University (3) · Massachusetts General Hospital (2) · University Hospital, Rouen (2) · University of Cincinnati (2) · University of Wisconsin, Madison (2) · Allan D Kirk, MD, PhD (1) · Amgen (1) · Andrew B Adams (1) · Brigham and Women's Hospital (1) · Columbia University (1) · Duke University (1) · East Carolina University (1) · ITB-Med LLC (1)
United States (52) · France (7) · Argentina (5) · Canada (4) · Germany (4) · Belgium (3) · Netherlands (3) · Spain (3) · Italy (2) · Mexico (2) · Norway (2) · Switzerland (2) · United Kingdom (2) · Australia (1) · Austria (1)
Kenneth Newell, MD, PhD (3) · Christian P. Larsen, MD, DPhil (2) · Flavio Vincenti, MD (2) · Nicole Turgeon, MD (2) · A.M. James Shapiro, MD, PhD (1) · Allan D. Kirk, M.D., Ph.D. (1) · Andrew B Adams, MD, PhD (1) · Annette M. Jackson, PhD (1) · Antonio Guasch, MD (1) · Arjang Djamali, M.D. (1) · Asif Sharfuddin, MD (1) · Bruce Kaplan, MD (1) · Christian Larsen, MD (1) · Christian P Larsen, MD, D.Phil (1)
PMID 21051752, PMID 23438305, PMID 24684552, PMID 26436448, PMID 28556519, PMID 29136317, PMID 30866104, PMID 31415033, PMID 32039559, PMID 32558199, PMID 33583120, PMID 33942491, PMID 34233921, PMID 34706967, PMID 36644348, PMID 37899481, PMID 39792912, PMID 40444214, PMID 40704545, PMID 42486389
UM1AI109565 (2), U01AI084150 (1)